Apr 11 |
Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet
|
Apr 11 |
Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
|
Apr 11 |
Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
|
Apr 10 |
Why Janux Therapeutics Stock Soared as the Market Sagged Today
|
Apr 10 |
Janux Therapeutics surges amid report of takeover interest
|
Apr 8 |
After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX)
|
Mar 28 |
Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know
|
Mar 22 |
Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade
|
Mar 20 |
Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst
|
Mar 20 |
Cantor starts Janux at overweight, cites TCE leadership position
|